Therapeutic Potential of Vitamin D in AGE/RAGE-related Cardiovascular Diseases

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2019 Jun 29

PMID 31250032

Citations 21

Authors

Ting-Wei Lee

Yu-Hsun Kao

Yi-Jen Chen

Tze-Fan Chao

Ting-I Lee

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) are among the leading threats to human health. The advanced glycation end product (AGE) and receptor for AGE (RAGE) signaling pathway regulates the pathogenesis of CVDs, through its effects on arterial stiffness, atherosclerosis, mitochondrial dysfunction, oxidative stress, calcium homeostasis, and cytoskeletal function. Targeting the AGE/RAGE pathway is a potential therapeutic strategy for ameliorating CVDs. Vitamin D has several beneficial effects on the cardiovascular system. Experimental findings have shown that vitamin D regulates AGE/RAGE signaling and its downstream effects. This article provides a comprehensive review of the mechanistic insights into AGE/RAGE involvement in CVDs and the modulation of the AGE/RAGE signaling pathways by vitamin D.

Citing Articles

The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.

Sadeghi M, Momeni A, Mirsaeidi F, Jamalian M, Amirpour A, Hadavi M Adv Biomed Res. 2024; 13:79.

PMID: 39512413 PMC: 11542689. DOI: 10.4103/abr.abr_380_23.

THBru attenuates diabetic cardiomyopathy by inhibiting RAGE-dependent inflammation.

Xu H, Hao S, Sun H, Dong X, Lin Y, Lou H Acta Pharmacol Sin. 2024; 45(10):2107-2118.

PMID: 38862818 PMC: 11420355. DOI: 10.1038/s41401-024-01307-7.

Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy.

Zeng Y, Li Y, Jiang W, Hou N Front Cardiovasc Med. 2024; 11:1375400.

PMID: 38596692 PMC: 11003275. DOI: 10.3389/fcvm.2024.1375400.

Targeting the Hallmarks of Aging with Vitamin D: Starting to Decode the Myth.

Ruggiero C, Tafaro L, Cianferotti L, Tramontana F, Macchione I, Caffarelli C Nutrients. 2024; 16(6).

PMID: 38542817 PMC: 10975458. DOI: 10.3390/nu16060906.

Molecular targets and mechanisms of on diabetic cardiomyopathy based on network pharmacology.

Wang Y, Wang Y, Jiang X, Li J World J Diabetes. 2023; 14(11):1659-1671.

PMID: 38077804 PMC: 10704204. DOI: 10.4239/wjd.v14.i11.1659.

References

Cantini C, Kieffer P, Corman B, Liminana P, Atkinson J, Lartaud-Idjouadiene I . Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension. 2001; 38(4):943-8. DOI: 10.1161/hy1001.096211. View

Dreyer G, Tucker A, Harwood S, Pearse R, Raftery M, Yaqoob M . Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. PLoS One. 2014; 9(7):e99461. PMC: 4090117. DOI: 10.1371/journal.pone.0099461. View

Pilz S, Verheyen N, Grubler M, Tomaschitz A, Marz W . Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol. 2016; 13(7):404-17. DOI: 10.1038/nrcardio.2016.73. View

Ihm S, Chang K, Kim H, Baek S, Youn H, Seung K . Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth.... Basic Res Cardiol. 2009; 105(3):399-407. DOI: 10.1007/s00395-009-0071-x. View

Qi D, Nie X, Wu S, Cai J . Vitamin D and hypertension: Prospective study and meta-analysis. PLoS One. 2017; 12(3):e0174298. PMC: 5373576. DOI: 10.1371/journal.pone.0174298. View

Brownlee M . Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992; 15(12):1835-43. DOI: 10.2337/diacare.15.12.1835. View

Pilz S, Iodice S, Zittermann A, Grant W, Gandini S . Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011; 58(3):374-82. DOI: 10.1053/j.ajkd.2011.03.020. View

Lee T, Kao Y, Lee T, Chen Y . ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes. Eur J Clin Invest. 2017; 47(9):675-683. DOI: 10.1111/eci.12789. View

Hegab Z, Mohamed T, Stafford N, Mamas M, Cartwright E, Oceandy D . Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide. FEBS Open Bio. 2017; 7(11):1672-1685. PMC: 5666397. DOI: 10.1002/2211-5463.12284. View

10.

Candido R, Forbes J, Thomas M, Thallas V, Dean R, Burns W . A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003; 92(7):785-92. DOI: 10.1161/01.RES.0000065620.39919.20. View

11.

Ku S, Hong J, Moon H, Jeong J, Mok H, Park S . Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. Arch Pharm Res. 2015; 38(7):1317-24. DOI: 10.1007/s12272-014-0527-x. View

12.

Lee T, Lee T, Chang C, Lien G, Kao Y, Chao T . Potential of vitamin D in treating diabetic cardiomyopathy. Nutr Res. 2015; 35(4):269-79. DOI: 10.1016/j.nutres.2015.02.005. View

13.

Bucciarelli L, Kaneko M, Ananthakrishnan R, Harja E, Lee L, Hwang Y . Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006; 113(9):1226-34. DOI: 10.1161/CIRCULATIONAHA.105.575993. View

14.

Tekabe Y, Luma J, Li Q, Schmidt A, Ramasamy R, Johnson L . Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging. 2012; 5(1):59-67. PMC: 3636550. DOI: 10.1016/j.jcmg.2011.09.016. View

15.

Larsen T, Mose F, Bech J, Hansen A, Pedersen E . Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens. 2012; 25(11):1215-22. DOI: 10.1038/ajh.2012.111. View

16.

Bikman B, Summers S . Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest. 2011; 121(11):4222-30. PMC: 3204836. DOI: 10.1172/JCI57144. View

17.

Schmidt A, Hori O, Chen J, Li J, Crandall J, Zhang J . Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of.... J Clin Invest. 1995; 96(3):1395-403. PMC: 185762. DOI: 10.1172/JCI118175. View

18.

Robinson-Cohen C, Hoofnagle A, Ix J, Sachs M, Tracy R, Siscovick D . Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013; 310(2):179-88. PMC: 4150653. DOI: 10.1001/jama.2013.7228. View

19.

Yan D, Luo X, Li Y, Liu W, Deng J, Zheng N . Effects of advanced glycation end products on calcium handling in cardiomyocytes. Cardiology. 2014; 129(2):75-83. DOI: 10.1159/000364779. View

20.

Koska J, Saremi A, Howell S, Bahn G, de Courten B, Ginsberg H . Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care. 2017; 41(3):570-576. PMC: 5829965. DOI: 10.2337/dc17-1740. View